VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

CONy 2021 | New migraine targets: AMY1 & PACAP

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, gives an overview of new targets for migraine therapy. A potential new target is the amylin subtype 1 receptor (AMY1), as a recent study has shown that an AMY1 analog, pramlintide, induces migraine-like attacks in patients. Other studies are also investigating pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that probably has a wider role in migraine pathophysiology than calcitonin gene-related peptide (CGRP). Pre-clinical data on this neuropeptide looks promising and monoclonal antibodies targeting PACAP are under development. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).


Advisory board, speaker bureau, investigational studies: Angelini, Assosalute, Bayer, Eli-Lilly, Lundbeck, Lusofarmaco, 1MED, MSD, Noema Pharma, Novartis, Teva, Visufarma, Zambon.